Zyto Group

Jan 20, 2021

LaingBuisson News By Financial terms have not been disclosed. Zyto’s three operating companies – Zytomed, ZytoVision and 42 Life Sciences – provide doctors with diagnostic tools to understand the genetic changes that occur in individual patients’ tumours. The approach permits precision medical treatment, in which doctors create more effective, customised care based on a genetic understanding of how disease is evolving in individual patients. “Our internal expertise – a majority of ArchiMed team members have science backgrounds and many have operational experience in medical or pathology labs – was key to understanding the potential of Zyto’s complex, industry-leading products,” said ArchiMed managing partner Vincent Guillaumot. “With our backing, these companies have the resources for further product innovation and for rapid international expansion,” he added. ArchiMed is acquiring its stake via its MED II fund, which closed on €315m (US$384.4m) in 2017. The Zyto investment, financed with equity and debt, is ArchiMed’s third transaction in the diagnostics industry in the last 24 months. It follows the carve-out from Poland’s Cormay of Diesse Diagnostica Senese, an Italian developer of innovative in vitro diagnostic systems (and a leading developer and manufacturer of a proprietary Covid-19 test) in May 2019 and the acquisition of Austria-based point-of-care diagnostics group EUROLyser and its distributor, EuroLab in February 2019.